Rituximab launch date

Rituximab was approved for medical use in1997 and is included in the World Health Organization's list of essential medicines. Rituximab is manufactured by Biogen and Genentech in the United States, Canada's Hoffmann-La Roche and the European Union, Chugai Pharmaceuticals, and Japan's Zenyaku Kogyo is sold jointly with Iran's AryoGen. Rituximab was launched in China in 2000. Rituximab is a drug used to treat certain autoimmune diseases and types of cancer. It is used in non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, Granulomatosis with polyangiitis, Idiopathic thrombocytopenic purpura, Pemphigus vulgaris, Myasthenia gravis and Epstein-Barr virus-Active mucocutaneous ulcers.

Rituximab may cause serious brain infections that can lead to disability or death, This infection is more likely to occur if you have used immunosuppressive drugs in the past, or if you have received rituximab from a stem cell transplant. To ensure that rituximab is safe for patients , tell your doctor if you have: liver disease or hepatitis; infection, including herpes, shingles, cytomegalovirus, chickenpox, parvovirus, West Nile virus, or hepatitis B or C; kidney disease; lung disease or breathing disorder; weak immune system; heart disease, angina (chest pain), or arrhythmia. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.